

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
2 July 2009 (02.07.2009)

PCT

(10) International Publication Number
WO 2009/080724 A1

(51) International Patent Classification:

C07D 413/04 (2006.01) A61P 37/00 (2006.01)
 C07D 217/06 (2006.01) A61P 17/00 (2006.01)
 C07D 217/22 (2006.01) A61K 31/4725 (2006.01)
 C07D 217/16 (2006.01) C07D 413/14 (2006.01)

(21) International Application Number:

PCT/EP2008/067963

(22) International Filing Date:

19 December 2008 (19.12.2008)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0725101.0 21 December 2007 (21.12.2007) GB

(71) Applicant (for all designated States except US): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HEER, Jag, Paul** [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow Essex CM19 5AW (GB). **HEIGHTMAN, Thomas, Daniel** [GB/GB]; c/o Glaxo-SmithKline, New Frontiers Science Park South, Third Avenue, Harlow Essex CM19 5AW (GB).

(74) Agents: **GRIFFITH, Johanna, Elise** et al.; Glaxo-SmithKline, Corporate Intellectual Property CN925.1, 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))


Published:

- with international search report


(54) Title: OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1P)




(57) Abstract: The present application discloses oxadiazole based compounds of Formula (I) active on sphingosine-1-phosphate (S1P) in particular useful to treat lupus erythematosus. A is phenyl or a 5 or 6-membered heteroaryl ring; B is selected from one of the following; Formulae: (a) (b) (c)



(a)



(b)



(c)